Heart Beam, Inc. BEAT
We take great care to ensure that the data presented and summarized in this overview for HeartBeam, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BEAT
View all-
Vanguard Group Inc Valley Forge, PA592KShares$1.61 Million0.0% of portfolio
-
Smith, Salley & Associates250KShares$680,0000.04% of portfolio
-
Geode Capital Management, LLC Boston, MA209KShares$567,6470.0% of portfolio
-
Ubs Group Ag162KShares$439,5920.0% of portfolio
-
Beacon Pointe Advisors, LLC Newport Beach, CA133KShares$362,6680.0% of portfolio
-
Stifel Financial Corp St. Louis, MO100KShares$272,0000.0% of portfolio
-
Kestra Private Wealth Services, LLC90.3KShares$245,5880.0% of portfolio
-
Pasadena Private Wealth, LLC Pasadena, CA82.6KShares$224,5600.04% of portfolio
-
State Street Corp Boston, MA65.3KShares$177,5420.0% of portfolio
-
Advisory Research Inc Chicago, IL50KShares$136,0000.02% of portfolio
Latest Institutional Activity in BEAT
Top Purchases
Top Sells
About BEAT
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Insider Transactions at BEAT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Kenneth Warwick Nelson Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+20.7%
|
-
|
|
Jun 12
2024
|
Michael R Jaff Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+30.64%
|
-
|
|
Jun 12
2024
|
Willem Elfrink Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+9.45%
|
-
|
|
Jun 12
2024
|
Mark E Strome > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+36.74%
|
-
|
|
Jun 12
2024
|
George De Urioste Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+32.38%
|
-
|
|
Jun 12
2024
|
Marga Ortigas Wedekind Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,185
+22.81%
|
-
|
|
Jun 12
2024
|
Richard Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,247
+22.81%
|
-
|
|
Sep 29
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,500
-13.21%
|
$11,000
$2.06 P/Share
|
|
Sep 28
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
8,000
-16.12%
|
$16,000
$2.04 P/Share
|
|
Sep 27
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
1,834
-3.56%
|
$3,668
$2.11 P/Share
|
|
Sep 26
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,000
-8.86%
|
$10,000
$2.09 P/Share
|
|
Sep 22
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
2,393
-4.07%
|
$4,786
$2.21 P/Share
|
|
Sep 21
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
100
-0.17%
|
$200
$2.41 P/Share
|
|
Sep 20
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
883
-1.48%
|
$1,766
$2.46 P/Share
|
|
Sep 18
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,000
-7.71%
|
$10,000
$2.46 P/Share
|
|
Sep 15
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
4,269
-6.18%
|
$8,538
$2.43 P/Share
|
|
Sep 14
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,000
-6.75%
|
$10,000
$2.17 P/Share
|
|
Sep 13
2023
|
George De Urioste Director |
SELL
Open market or private sale
|
Direct |
5,000
-3.21%
|
$5,000
$1.93 P/Share
|
|
Jul 13
2023
|
Willem Elfrink Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,961
+7.76%
|
-
|
|
Jul 13
2023
|
Richard Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,948
+23.25%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 395K shares |
|---|
| Open market or private sale | 43K shares |
|---|